| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1877646 | Applied Radiation and Isotopes | 2013 | 10 Pages |
68Gallium-PET (68Ga-PET) agents have significant clinical promise. The radionuclide can be produced from a 68Ge/68Ga generator on site and is a convenient alternative to cyclotron-based PET isotopes. The short half-life of 68Ga permits imaging applications with sufficient radioactivity while maintaining patient dose to an acceptable level. Furthermore, due to superior resolution, 68Ga-PET agents have the ability to replace current SPECT agents in many applications. This article outlines the upcoming agents and challenges faced during the translational development of 68Ga agents.
► Novel preclinical probes for 68Ga PET are reviewed. ► Pretargeting strategies for Ga68 imaging are discussed. ► The importance of specific activity in development of 68Ga-probes is discussed.
